Rachelle Jacques joined Enzyvant as CEO in 2019 to prepare for the next phase of the company, focusing investments and capabilities on the development of transformative regenerative therapies for rare diseases. Under her leadership, Enzyvant is poised for a 2021 regulatory approval and launch of investigative RVT-802, designated by the U.S. Food and Drug Administration as a Regenerative Medicine Advanced Therapy (RMAT).
Rachelle brings to Enzyvant strong global and U.S. background in strategic, cross-functional leadership roles spanning finance, business operations, manufacturing, and commercial, including the successful launches of several novel therapies for rare diseases. She served as the Senior Vice President and Global Complement Franchise Head at Alexion, where she was responsible for global franchise strategy development and execution across the therapeutic areas of hematology, nephrology, and neurology. She was Vice President of U.S. Hematology Marketing at the Shire, which acquired Baxalta in 2016, and served as Vice President of Business Operations at Baxalta after its spinoff from Baxter. Rachelle held multiple leadership positions at Baxter, including Vice President of Finance, U.S. BioScience Business. Earlier in her career, she served in various roles at Dow Corning Corporation, including operational management positions in the U.S., Europe, and China.
Rachelle currently serves on the Board of Directors of Corbus Pharmaceuticals and Viela Bio. She is co-chair of the Alliance for Regenerative Medicine (ARM) Tissue Engineering & Biomaterials Committee and is a founding member of the ARM Action for Equality Task Force.
Rachelle received her B.A. degree in business administration from Alma College.